{"entity":{"id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Pegylated liposomal doxorubicin in ovarian cancer, run by TILT Biotherapeutics Ltd., active and no longer recruiting.","summary":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. is a phase 1/2 interventional study registered as NCT05271318 by TILT Biotherapeutics Ltd., with 29 participants planned, started 2022-05-17 and due to reach its primary completion in 2027-03. Interventions recorded: TILT-123, pembrolizumab, pegylated liposomal doxorubicin. Conditions listed: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05271318","url":"https://clinicaltrials.gov/study/NCT05271318"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","pegylated-liposomal-doxorubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05271318","phase":"1/2","setting":"A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer","sponsor":"TILT Biotherapeutics Ltd.","enrolled":29,"outcomes":[]},"route":"/trials/nct05271318/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"tilt-123","kind":"drug","name":"TILT-123","route":"/drugs/tilt-123/"}]}}